「ケタミン」の版間の差分

ナビゲーションに移動 検索に移動
7,301 バイト追加 、 2020年8月23日 (日)
編集の要約なし
編集の要約なし
編集の要約なし
9行目: 9行目:


{{box|text= アリルシクロヘキシルアミン系の解離性麻酔薬であり、世界保健機関による必須医薬品の一つである。薬物乱用が問題になり麻薬指定された。精神医学領域では、ケタミンは統合失調症モデルとして使用されているが、近年、ケタミンの即効性抗うつ効果が注目されている。}}
{{box|text= アリルシクロヘキシルアミン系の解離性麻酔薬であり、世界保健機関による必須医薬品の一つである。薬物乱用が問題になり麻薬指定された。精神医学領域では、ケタミンは統合失調症モデルとして使用されているが、近年、ケタミンの即効性抗うつ効果が注目されている。}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 477168837
| IUPAC_name = (''RS'')-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
| image = Ketamine2DCSD.svg
| width = 150px
| image2 = S-ketamine-from-HCl-xtal-3D-balls.png
| width2 = 175px
| alt2 = (''S'')-Ketamine ball-and-stick model
<!--Clinical data-->
| tradename = Ketalar, others
| Drugs.com = {{drugs.com|monograph|ketamine-hydrochloride}}
| DailyMedID = Ketamine
| licence_US = Ketamine
| pregnancy_AU = B3
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">https://www.drugs.com/pregnancy/ketamine.html</ref>
| pregnancy_US = N
| pregnancy_US_comment = <ref name="Drugs.com pregnancy" />
| legal_status = Rx-only
| legal_AU = S8
| legal_CA = Schedule I
| legal_UK = Class B
| legal_US = Schedule III
| legal_UN = Unscheduled
| routes_of_administration = Any<ref><pubmed>28657160</pubmed></ref><ref><pubmed> 28339431 </pubmed></ref><ref name="MathewZarate2016"><pubmed>24257811 </pubmed></ref>
| addiction_liability = Low–moderate<ref name="NHM-PCP and ketamine">'''Malenka RC, Nestler EJ, Hyman SE'''<br>Chapter 15: Reinforcement and Addictive Disorders |quote=Phencyclidine (PCP or angel dust) and ketamine (also known as special K) are structurally related drugs... their reinforcing properties and risks related to compulsive abuse<br>edited by Sydor A, Brown RY, Molecular Neuropharmacology: A Foundation for Clinical Neuroscience 2nd ed. pp. 374–375 (2009) McGraw-Hill Medical, New York</ref><!--Start widen drugbox--><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--End widen drugbox-->
| class = [[NMDA receptor antagonists]]; [[General anesthetics]]; [[Dissociative hallucinogen]]s; [[Analgesic]]s; [[Antidepressant]]s
<!--Pharmacokinetic data-->
| bioavailability =
* [[Intravenous therapy|Intravenous]]: 100%<ref name="MathewZarate2016" />
* [[Intramuscular injection|Intramuscular]]: 93%<ref name="MathewZarate2016" />
* [[Subcutaneous injection|Subcutaneous]]: high<ref name="Mao2016">'''Jianren Mao. (2016).'''<br>Opioid-Induced Hyperalgesia <br>CRC Press</ref>
* [[Epidural administration|Epidural]]: 77%<ref name="Kintz2014">'''Pascal Kintz. (2014).'''<br>Toxicological Aspects of Drug-Facilitated Crimes<br>Elsevier Science</ref>
* [[Intranasal administration|Intranasal]]: 8–50%<ref name="MathewZarate2016" /><ref name="pmid29736744"><pubmed> 29736744</pubmed></ref><ref name="sinner"><pubmed> 18175098 </pubmed></ref>
* [[Sublingual administration|Sublingual]]: 24–30%<ref name="MathewZarate2016" /><ref name="Hashimoto2019"><pubmed>31215725</pubmed></ref>
* [[Rectal administration|Rectal]]: 11–30%<ref name="Nemeroff2017">
'''Alan F. Schatzberg & Charles B. Nemeroff. (2017).'''<br>The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition<br>American Psychiatric Pub, pp550-.</ref>
<ref name=Zhang2018><pubmed> 30513009</pubmed> </ref>
* [[Oral administration|By mouth]]: 16–29%<ref name="Kintz2014" /><ref name="DickmanSchneider2016">'''Andrew Dickman & Jennifer Schneider. (2016).'''<br>The Syringe Driver: Continuous Subcutaneous Infusions in Palliative Care<br>Oxford University Press, pp. 114-</ref><ref name=Zhang2018 />
| protein_bound = 12–47% (low)<ref name="Kintz2014" /><ref name="sinner" /><ref name="DowdJohnson2016">'''Frank J. Dowd, Bart Johnson & Angelo Mariotti. (2016).'''<br>Pharmacology and Therapeutics for Dentistry – E-Book<br>Elsevier Health Sciences, pp235–</ref>
| metabolism = [[Liver]] ([[demethylation|''N''-demethylation]]):<ref name="MathewZarate2016" /><ref><pubmed>12065445</pubmed></ref>
* Major: [[CYP3A4]]
* Minor: [[CYP2B6]], [[CYP2C9]]
| metabolites =
* [[Norketamine]]
* [[Dehydronorketamine]]
* [[Hydroxynorketamine]]
* [[Conjugation (biochemistry)|Conjugates]]<ref name="Levine2003">{{cite book |author=Barry Levine |title=Principles of Forensic Toxicology |url=https://books.google.com/books?id=k7BInEQ-iqgC&pg=PA282 |year=2003 |publisher=[[American Association for Clinical Chemistry]] |isbn=978-1-890883-87-4 |pages=282– |url-status=live |archiveurl=https://web.archive.org/web/20170908185726/https://books.google.com/books?id=k7BInEQ-iqgC&pg=PA282 |archivedate=8 September 2017 }}</ref>
| onset =
* Intravenous: seconds<ref name="sinner" />
* Intramuscular: 1–5 min<ref name="sinner" /><ref name="Quibell2011">{{cite journal |last1= Quibell |first1= R |last2= Prommer |first2= EE |last3= Mihalyo |first3= M |last4= Twycross |first4= R |last5= Wilcock |first5= A |displayauthors= 4 |title= Ketamine* |journal= [[Journal of Pain and Symptom Management]] |date= March 2011 |volume= 41 |issue= 3 |pages= 640–9 |doi= 10.1016/j.jpainsymman.2011.01.001 |pmid= 21419322 |url= http://www.jpsmjournal.com/article/S0885-3924%2811%2900046-7/fulltext |type= Therapeutic Review|doi-access= free }}</ref>
* Subcutaneous: 15–30 min<ref name="Quibell2011" />
* Insufflation: 5–10 min<ref name="sinner" />
* By mouth: 15–30 min<ref name="sinner" /><ref name="Quibell2011" />
| elimination_half-life =
* Ketamine: 2.5–3 hours<ref name="sinner" /><ref name="MathewZarate2016" />
* Norketamine: 12 hours<ref name="Quibell2011" ><pubmed> 21419322</pubmed></ref>
| duration_of_action =
* Intramuscular: 0.5–2 hours<ref name="Quibell2011" />
* Insufflation: 45–60 min<ref name="sinner" />
* By mouth: 1–6+ hours<ref name="sinner" /><ref name="Quibell2011" />
| excretion =
* [[Urine]]: 91%<ref name="MathewZarate2016" />
* [[Feces]]: 1–3%<ref name="MathewZarate2016" />
<!--Identifiers-->
| IUPHAR_ligand = 4233
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 6740-88-1
| CAS_supplemental = {{plainlist|
* 1867-66-9 ([[hydrochloride]])
* 33643-46-8 ([[esketamine]])
* 33643-49-1 ([[arketamine]])}}
| ATC_prefix = N01
| ATC_suffix = AX03
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6121
| PubChem = 3821
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01221
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3689
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 690G0D6V8H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08098
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 742
| synonyms = CI-581; CL-369; CM-52372-2<ref name="MortonHall2012">'''I.K. Morton, & Judith M. Hall. (2012).'''<br>Concise Dictionary of Pharmacological Agents: Properties and Synonyms<br>Springer Science & Business Media, pp159–</ref>
<!--Chemical data-->
| C=13 | H=16 | Cl=1 | N=1 | O=1
| molecular_weight = 237.725
| chirality = [[Racemic mixture]]:<ref name="sinner" />
* [[Esketamine]] (''S''(+)-isomer)
* [[Arketamine]] (''R''(−)-isomer)
| SMILES = Clc1ccccc1C2(NC)CCCCC2=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YQEZLKZALYSWHR-UHFFFAOYSA-N
<!--Physical data-->
| melting_point = 258
| melting_high = 261
<!--Empty-->
| alt=|caption=|type=|MedlinePlus=|licence_EU=|pregnancy_category=
}}


== 歴史 ==
== 歴史 ==

案内メニュー